BCL2 and B-cell non-Hodgkin lymphoma: Utilizing these compounds as molecular tools to modulate BCL2 i-motif formation within B-cell lymphoma and breast cancer cell lines, BCL2 mRNA expression was substantially reduced, with less i-motif formation, while the presence of a stable i-motif increased mRNA levels.